ReviewThe Lancet. Infectious diseases2022
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation.
Review in The Lancet. Infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Article
- Epidemiological, virological, and clinical characteristics of dengue in the Lao People's Democratic Republic, 2022-2023: a cross-sectional study.Tropical medicine and health · 2026Article
- Knowledge and perceptions on dengue among internship medical students and rural physicians in Ecuador: a cross-sectional study, 2025.BMC medical education · 2026Article
- Dengue's Clinical Course in One of Colombia's Most Endemic Areas: Impact of Endemic and Epidemic Periods.The American journal of tropical medicine and hygiene · 2026Observational
- Clinical profile and predictors of adverse outcomes in pediatric dengue fever presenting with febrile illness: a prospective observational study in Burao, Somaliland.Frontiers in pediatrics · 2026Article
- Discovery of a Novel Non-Nucleoside Inhibitor of RNA-Dependent RNA Polymerase Against Dengue Virus.MedComm · 2025Article
- Epidemiology and severity risk factors of dengue virus infection during the 2023-2024 outbreak in Colombia.PLoS neglected tropical diseases · 2025Article
- Frequency of dengue virus-specific T cells is related to infection outcome in endemic settings.JCI insight · 2025Article
- Trends and insights in dengue virus research globally: a bibliometric analysis (1995-2023).Journal of translational medicine · 2024Article
- Dengue.Lancet (London, England) · 2024Review
- Human coronavirus OC43-elicited CD4Nature communications · 2024Article
- A Novel, Comprehensive A129 Mouse Model for Investigating Dengue Vaccines and Evaluating Pathogenesis.Vaccines · 2023Article
- Enrollment of dengue patients in a prospective cohort study in Umphang District, Thailand, during the COVID-19 pandemic: Implications for research and policy.Health science reports · 2023Article
- Evaluation of remote radiologist-interpreted point-of-care ultrasound for suspected dengue patients in a primary health care facility in Colombia.Infectious diseases of poverty · 2023Article
- Serum biomarkers and anti-flavivirus antibodies at presentation as indicators of severe dengue.PLoS neglected tropical diseases · 2023Article
- Extracellular Vesicles Are Conveyors of the NS1 Toxin during Dengue Virus and Zika Virus Infection.Viruses · 2023Article
- SUMOylation Is Essential for Dengue Virus Replication and Transmission in the MosquitoFrontiers in microbiology · 2022Article
- Development of Novel Dengue NS1 Multiplex Lateral Flow Immunoassay to Differentiate Serotypes in Serum of Acute Phase Patients and Infected Mosquitoes.Frontiers in immunology · 2022Article
- Regional Variation in Dengue Virus Serotypes in Sri Lanka and Its Clinical and Epidemiological Relevance.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 4 countries.
Funding
Abstract
The most severe consequences of dengue virus infection include shock, haemorrhage, and major organ failure; however, the frequency of these manifestations varies, and the relative contribution of pre-existing anti-dengue virus antibodies, virus characteristics, and host factors (including age and comorbidities) are not well understood. Reliable characterisation of the epidemiology of severe dengue first depends on the use of consistent definitions of disease severity. As vaccine trials have shown, severe dengue is a crucial interventional endpoint, yet the infrequency of its occurrence necessitates the inclusion of thousands of study participants to appropriately compare its frequency among participants who have and have not been vaccinated. Hospital admission is frequently used as a proxy for severe dengue; however, lack of specificity and variability in clinical practices limit the reliability of this approach. Although previous infection with a dengue virus is the best characterised risk factor for developing severe dengue, the influence of the timing between dengue virus infections and the sequence of dengue virus infections on disease severity is only beginning to be elucidated. To improve our understanding of the diverse factors that shape the clinical spectrum of disease resulting from dengue virus infection, prospective, community-based and clinic-based immunological, virological, genetic, and clinical studies across a range of ages and geographical regions are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.